BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

MedImmune (AZN) to Present Seven Posters on Influenza, Respiratory Syncytial Virus at the Annual Pediatric Academic Societies Meeting


5/6/2013 6:25:13 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

GAITHERSBURG, Md., May 4, 2013 /PRNewswire/ -- MedImmune announced today it will conduct seven poster and/or presentations at the Pediatric Academic Societies (PAS) Meeting at the Walter E. Washington Convention Center in Washington DC, May 4-7, 2013. These abstracts advance the body of existing data and knowledge around influenza and respiratory syncytial virus (RSV) prevention, highlighting MedImmune's continued commitment to patient health.

MedImmune posters to be presented at PAS regarding influenza include:

  • Efficacy of Live Attenuated Influenza Vaccine Against Moderate to Severe Versus Mild Influenza Illness in Children. Ambrose CS, Wu X, Belshe RB. Platform Presentation Session: May 4, 2013, 9:45 AM, Session: Section 115- Infectious Diseases, Vaccines & Infections

  • Serum HAI Antibody Response to LAIV in 2 to 49 Year Olds.Coelingh K, Wu X, Mallory R, Ambrose CS. Poster Session: May 4, 2013, 1:00 PM 4:00 PM; Exhibit Hall D/E; Board: 493

MedImmune posters to be presented at PAS regarding RSV include:

  • Burden of and Risk Factors for Medically Attended RSV Illness in 3235 w/GA Infants Not Receiving RSV Prophylaxis.Groothuis J, Wu X, Makari D, Ambrose CS. Poster Session: May 4, 2013, 1:00 pm 4:00 pm, Publication Number: 1500.4. Session: 1500 Epidemiology, Exhibit Hall D/E, Board: 4

  • Risk for Medically Attended RSV Illness in 3234 Weeks vs. 35 Weeks Gestational Age Preterm Infants Not Receiving Palivizumab. Groothuis J, Wu X, Makari D, Ambrose CS. Publication Number 1500.3. Poster Session: May 4, 2013, 1:00 pm 4:00 pm. Session: 1500 Epidemiology, Exhibit Hall D/E, Board: 3

  • Respiratory Syncytial Virus Surveillance, 20072012: Results from RSVAlertĀ®, a U.S. National Hospital-Based Surveillance Program.Boron M, Kumar V, McGuiness CB, Saunders B, Rabon-Stith K. Poster Session: May 4, 2013, 1:00 pm 4:00 pm, Publication Number: 1500.7, Session: 1500 Epidemiology, Exhibit Hall D/E, Board: 7

  • Impact of Partial Prophylaxis with Palivizumab on RSV Hospitalizations among Commercially-Insured High-Risk Preterm Infants. Ryan K, Stewart D, Frogel M, Becker L, Pinsky B. Poster Session: May 5, 2013, 4:15 pm 7:30 pm. Publication Number: 2915.209. Session: 2915 Infectious Diseases, Exhibit Hall D/E, Board: 209

  • Pharmacokinetic (PK) Profile of Palivizumab (Pali) in Premature Infants. La Via WV, Makari D, Yu X, Robbie GJ. Poster Session: May 7, 2013, 10:00 am 2:00 pm. Publication Number: 4514.228. Session: 4514 Neonatal Infectious Diseases / Immunology, Exhibit Hall D/E, Board: 228

Additional information about the 2013 PAS conference can be found at
http://www.pas-meeting.org/2013DC/default.asp

About MedImmune
MedImmune is the worldwide biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. MedImmune has approximately 2,500 employees globally, with its headquarters located in Gaithersburg, Md., one of AstraZeneca's three global R&D centers. For more information, please visit www.medimmune.com.

SOURCE MedImmune

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

MedImmune
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES